OSR (NASDAQ:OSRH) Shares Climb 1.3% – Time to Buy?

OSR Holdings, Inc. (NASDAQ:OSRH) traded up 1.3% during mid-day trading on Tuesday. The stock traded as high as $0.2350 and last traded at $0.2076. Approximately 232,501 shares changed hands during trading, a decline of 96% from the average session volume of 6,002,917 shares. The stock had previously closed at $0.2050.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of OSR in a research report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, OSR presently has an average rating of “Sell”.

OSR Trading Down 8.5%

The firm has a market capitalization of $8.67 million, a price-to-earnings ratio of -0.67 and a beta of 0.49. The firm has a 50 day moving average price of $0.30 and a two-hundred day moving average price of $0.41.

OSR (NASDAQ:OSRH) last posted its earnings results on Friday, August 14th. The company reported ($0.02) earnings per share (EPS) for the quarter. OSR had a negative return on equity of 8.36% and a negative net margin of 593.15%.The business had revenue of $0.32 million for the quarter.

Institutional Investors Weigh In On OSR

A hedge fund recently bought a new position in OSR stock. Citadel Advisors LLC bought a new stake in OSR Holdings, Inc. (NASDAQ:OSRH) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 127,810 shares of the company’s stock, valued at approximately $40,000. Citadel Advisors LLC owned 0.36% of OSR at the end of the most recent quarter. Institutional investors own 55.30% of the company’s stock.

OSR Company Profile

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.